Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2014 by Prof. Dr. med. Ekkehard Gruenig, Heidelberg University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Prof. Dr. med. Ekkehard Gruenig, Heidelberg University Identifier:
First received: June 25, 2007
Last updated: July 1, 2014
Last verified: July 2014
In Patients with rheumatic disease exercise training is a well established element of therapy. In contrast patients with severe pulmonary hypertension are advised to avoid physical exertion and must not perform exercise training. This study aims to evaluate the effectivity and safety of a low-dose training program in patients with pulmonary hypertension and rheumatic disease.

Condition Intervention Phase
Pulmonary Hypertension
Connective Tissue Disease
Behavioral: exercise training
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension

Resource links provided by NLM:

Further study details as provided by Prof. Dr. med. Ekkehard Gruenig, Heidelberg University:

Primary Outcome Measures:
  • Change in the 6-minute walking distance [ Time Frame: after 3 weeks and after 15 weeks compared to baseline. ]
  • Quality of life (SF-36) [ Time Frame: baseline and 15 weeks ]

Secondary Outcome Measures:
  • change in inflammatory parameters (BKS, CRP, Leucocytes), change in inflammatory cytokines (TNF-α), change in parameters of the vascular endothelium (Endothelin, PDGF, VEGF), and endothelial progenitor cells [ Time Frame: baseline and 15 weeks ]
  • Physical capacity in the cardiopulmonary exercise testing (Watt) [ Time Frame: baseline, 3 weeks, 15 weeks ]
  • change of peak oxygen consumption and other parameters of cardiopulmonary exercise testing. [ Time Frame: baseline, 3 weeks, 15 weeks ]
  • hemodynamic parameters: dimension and pump function of the right and the left ventricle. [ Time Frame: baseline, 15 weeks ]
  • change in systolic pulmonary arterial pressure at rest and during exercise [ Time Frame: baseline, 3 weeks, 15 weeks ]

  • change of NTproBNP-value [ Time Frame: baseline, 3 weeks, 15 weeks ]

Estimated Enrollment: 45
Study Start Date: July 2011
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: exercise training group
exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)
Behavioral: exercise training
exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
No Intervention: Control group without exercise training
continuation of sedentary lifestyle without advice for specific exercise training


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Informed consent
  2. Men and women 18 - 80 years
  3. Diagnosed rheumatic disease: rheumatoid arthritis, Collagenosis (Systemic Lupus Erythematodes, Systemic Sclerosis, Sjögren-Syndrome, Sharp-Syndrome, Crest-Syndrome, Mixed connective tissue disease)
  4. Symptomatic PAH (WHO- functional class II-IV) invasively diagnosed by right heart catheterisation

    • Mean pulmonary artery pressure (mPAP) > 25 mmHg
    • Pulmonary capillary wedge pressure (PCWP) > 15 mmHg
    • Pulmonary vascular resistance (PVR) at baseline >320 dyn.sec/cm5 patients under optimized medical treatment since at least 2 ½ months

Exclusion Criteria:

  1. Other forms of PAH.
  2. Pregnancy or lactation
  3. Change in medication during the last 2 ½ months
  4. Patients with signs of right heart decompensation
  5. Severe impairment of walking
  6. Unclear diagnosis
  7. No invasive diagnosis of PH
  8. Acute illness, infection, fever
  9. Severe lung disease with FEV1 <50% and TLC< 70% below reference
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00491309

Contact: Ekkehard Gruenig, MD +49 6221 396 80 53

Thoraxclinic at the University Hospital Heidelberg Recruiting
Heidelberg, Baden-Wuerttemberg, Germany, 69126
Principal Investigator: Ekkehard Gruenig, MD         
Sponsors and Collaborators
Heidelberg University
Principal Investigator: Ekkehard Gruenig, MD Thoraxclinic at the University Hospital Heidelberg
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Dr. med. Ekkehard Gruenig, Prof. Dr. med. Ekkehard Grünig, Heidelberg University Identifier: NCT00491309     History of Changes
Other Study ID Numbers: Reha PH Rheumatic
Study First Received: June 25, 2007
Last Updated: July 1, 2014

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Hypertension, Pulmonary
Connective Tissue Diseases
Vascular Diseases
Cardiovascular Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Autoimmune Diseases
Immune System Diseases
Lung Diseases
Respiratory Tract Diseases processed this record on May 25, 2017